Examination of a role for idiotypy in the disease remission of a long-term survivor of adult T cell leukemia treated with anti-Tac antibody

Leukemia

Volumn 12, Issue 6, 1998, Pages 982-991

  Kingsbury, G A ^a,b   Waldmann, T A ^c   Junghans, R P ^a  

^a BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^b Millenium Therapeutics   (United States)

^c NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Anti idiotype antibodies; ATL; Human; Immunotherapy

Indexed keywords

IDIOTYPIC ANTIBODY; INTERLEUKIN 2 RECEPTOR; T LYMPHOCYTE ANTIBODY;

AGED; ARTICLE; CANCER IMMUNOTHERAPY; CASE REPORT; HUMAN; LEUKEMIA REMISSION; MALE; PRIORITY JOURNAL; T CELL LEUKEMIA;

EID: 0031835358     PISSN: 08876924     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.leu.2401048     Document Type: Article

References (17)

1. Waldmann TA, Pastan IH, Gansow, OA, Junghans RP. The multichain interleukin-2 receptor: a target for immunotherapy. Ann Intern Med 1992; 116: 148-160.
2. Strom TB, Kelley VR, Murphy JR, Nichols J, Woodworth TG. Interleukin-2 receptor-directed therapies: antibody-or cytokine-based targeting molecules. Annu Rev Med 1993; 44: 343-353.
3. Murphy EL, Hanchard B, Figueroa JP, Gibbs WN, Lofters WS, Campbell M, Goedert JJ, Blattner WA. Modelling the risk of adult T-cell leukemia/lymphoma in persons infected with human T-lymphotropic virus type I. Int J Cancer 1989; 43: 250-253.
4. Waldmann TA, White JD, Goldman CK, Top L, Grant A, Bamford R, Roessler E, Horak ID, Zaknoen S, Kasten-Sportes C, England R, Horak E, Mishra B, Dipre M, Hale P, Fleisher TA, Junghans RP, Jaffe ES, Nelson DL. The IL-2 receptor: a target for monoclonal antibody treatment of human T-cell lymphotrophic virus 1-induced adult T-cell leukemia. Blood 1993; 82: 1701-1702.
5. Meeker TC, Lowder J, Maloney DC, Miller RA, Thielmans K, Warnke R, Levy R. A clinical trial of anti-idiotype therapy for B cell malignancy. Blood 1985; 65: 1349-1363.
6. Norman DJ, Chatenoud L, Cohen D, Goldman M, Shield CF III. Consensus statement regarding OKT3-induced cytokine-release syndrome and human antimouse antibodies. Transplant Proc 1993; 23: 89-92.
7. Jerne NK. Towards a network theory of the immune system. Ann Immunol Inst Pasteur (Paris) 1974; 125C: 373-389.
8. Jaffers GJ, Fuller TC, Cosimi AB, Russel PS, Winn HJ, Colvin RB. Monoclonal antibody therapy. Anti-idiotypic and non-antiidiotypic antibodies to OKT3 arising despite intense immunosuppression. Transplantation 1986; 41: 572-578.
9. Rose B, Gillespie A, Wunderlich D, Kelley K, Dzuiba J, Shedd D, Cahill K, Zerler B. Differential effects of a murine and chimeric mouse/human anti-interleukin-2 receptor antibody on human T-cell proliferation. Immunology 1992; 76: 452-459.
10. Clendeninn NJ, Nethersell ABW, Scott JE, Collier MA. Phase I/II trials of CAMPATH-1H, a humanized anti-lymphocyte monoclonal antibody (MoAb), in non-Hodgkin's lymphoma (NHL) and chronic lymphocytic leukemia (CLL). Blood 1992; 80 (Suppl. 1): 158a.
11. Schäffner M, François C, Kaluza B, Hock H, Jacques Y, Weidle UH. Chimeric interleukin 2 receptor alpha chain antibody derivatives with fused mu and gamma chains permit improved recruitment of effector functions. Mol Immunol 1995; 32: 9-20.
12. Anasetti C, Hansen JA, Waldmann T, Binger M-H, Mould D, Satoh H, Appelbaum FR, Deeg HJ, Doney K, Martin PJ, Nash R, Sullivan KM, Witherspoon RP, Storb R. Treatment of acute graft-versus-host disease with a humanized monoclonal antibody specific for the IL-2 receptor. Blood 1992; 80 (Suppl. 1) 373a.
13. Pankewycz OG, Hassarjian R, Chang C, Strom TB, Kelley VE. Anti-interleukin-2 receptor monoclonal antibody therapy induces anti-idiotypic antibodies in mice that block both in vitro and in vivo activity. J Autoimmun 1988; 1: 119-130.
14. Bentley GA, Boulot G, Riottot MM, Poljak RJ. Three-dimensional structure of an idiotope-anti-idiotope complex. Nature 1990; 348: 254-257.
15. Garcia KC, Desiderio SV, Ronco PM, Verroust PJ, Amzel LM. Recognition of angiotensin II; antibodies at different levels of an idiotypic network are superimposable. Science 1992; 257: 528-531.
16. Baum RP, Niesen A, Hertel A, Nancy A, Hess H, Donnerstag B, Sykes TR, Sykes CJ, Suresh MR, Noujaim AA, Hör G. Activating anti-idiotypic human anti-mouse antibodies for immunotherapy of ovarian carcinoma. Cancer Suppl 1994; 73: 1121-1125.
17. Carreno M, Yang WC, Esquenazi V, Fuller L, Burke G, Milgrom M, Roth D, Ranjan D, Miller J. OKT3 induction via idiotypic networks of mirror-image immunosuppressive antiimmunoglobulins in renal transplant recipients. Transplantation 1990; 49: 408-415.